BioXcel Therapeutics (BTAI) FCF Margin (2022 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly FCF Margin of 5732.52% for Q1 2026, up 143593.0% year-over-year from N/an in Q1 2025, and down 3.27% quarter-over-quarter from 5550.78% in Q4 2025.
BioXcel Therapeutics (BTAI) FCF Margin (2022 - 2026) Analysis & Trends
BioXcel Therapeutics' FCF Margin history runs 5 years deep, the most recent figure standing at 5732.52% for Q1 2026.
- In Q1 2026, FCF Margin rose 143593.0% year-over-year to 5732.52%; the TTM figure through Mar 2026 stood at 8438.38% (down 485501.0% YoY), while the FY2025 annual figure was 8974.3%, down 579570.0% from the prior year.
- FCF Margin for Q1 2026 stood at 5732.52%, down from 5550.78% in the prior quarter.
- The five-year high for FCF Margin was 2099.09% in Q2 2024, with the low at 25414.08% in Q1 2023.
- The 5-year median for FCF Margin is 7634.58% (2024), against an average of 10390.81%.
- The sharpest annual moves came in 2024 and 2025: FCF Margin jumped 2237181 bps in 2024, then tumbled 1153583 bps in 2025.
- BioXcel Therapeutics' FCF Margin stood at 16234.87% in 2022, then soared by 56 bps to 7144.41% in 2023, then soared by 43 bps to 4046.17% in 2024, then sank by 37 bps to 5550.78% in 2025, then declined by 3 bps to 5732.52% in 2026.
- Business Quant data shows BTAI's FCF Margin at 5732.52% in Q1 2026, 5550.78% in Q4 2025, and 19170.41% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 7.41% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 21.80% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 14.87% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 26.25% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 8.76% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 13.41% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 17.84% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.26 Mn | 24.26 Mn | 160,000.00 | -3,350.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,350.55% |
| Mar 31, 2026 | -5,732.52% |
| Dec 31, 2025 | -5,550.78% |
| Sep 30, 2025 | -19,170.41% |
| Jun 30, 2025 | -10,479.17% |
| Mar 31, 2025 | -7,168.45% |
| Dec 31, 2024 | -4,046.17% |
| Sep 30, 2024 | -7,634.58% |
| Jun 30, 2024 | -2,099.09% |
| Mar 31, 2024 | -3,042.27% |
| Dec 31, 2023 | -7,144.41% |
| Sep 30, 2023 | -11,021.70% |
| Jun 30, 2023 | -8,360.18% |
| Mar 31, 2023 | -25,414.08% |
| Dec 31, 2022 | -16,234.87% |
| Sep 30, 2022 | -22,763.50% |